However, in ATLANTIC, a phase 2, open-label, single-arm trial, the effect of durvalumab treatment was assessed in patients with NSCLC; cohort 1 comprised EGFR+/ALK+ NSCLC patients, and the results for this cohort showed that EGFR+ NSCLC patients with ≥25% of tumor cells expressing PD-L1 benefit from ICIs (16). Here, ALK is linked to non-small cell lung carcinoma.